Recce Pharmaceuticals (FRA:R9Q) Institutional Ownership: 78.57% (As of Aug. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:R9Q Recce Pharmaceuticals Ltd FRA:R9Q
23 GF Score
Price €0.20
! 4 Warning Signs
View Full Analysis

What is Recce Pharmaceuticals Institutional Ownership?

Recce Pharmaceuticals FRA:R9Q -0.51% 23 Institutional Ownership is 78.57% as of Aug. 14, 2026. GuruFocus rates FRA:R9Q with a GF Score™ of 23/100. The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Recce Pharmaceuticals's institutional ownership is 78.57%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Recce Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Recce Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 0.00%.

Recce Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Recce Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recce Pharmaceuticals Institutional Ownership Chart

Recce Pharmaceuticals Historical Data

The historical data trend for Recce Pharmaceuticals can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 75.63 75.63 75.62 75.62 75.62 75.62 75.64 75.62 78.57 78.57
FRA:R9Q
23GF Score
Recce Pharmaceuticals Ltd FRA:R9Q
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recce Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 78.57% mean?
Recce Pharmaceuticals (FRA:R9Q) has a Institutional Ownership of 78.57% as of Aug. 14, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Recce Pharmaceuticals and its competitors.
Is Recce Pharmaceuticals' Institutional Ownership too high?
Recce Pharmaceuticals' current Institutional Ownership is 78.57%. Overall, Recce Pharmaceuticals has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Recce Pharmaceuticals' Institutional Ownership compare to VRTX and REGN?
Recce Pharmaceuticals' Institutional Ownership of 78.57% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Recce Pharmaceuticals and its competitors. Recce Pharmaceuticals's current Institutional Ownership is 78.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recce Pharmaceuticals stock overvalued right now?
Recce Pharmaceuticals (FRA:R9Q) has a current Institutional Ownership of 78.57%. The current Institutional Ownership is 78.57%. Recce Pharmaceuticals' overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Recce Pharmaceuticals (FRA:R9Q), the current Institutional Ownership is 78.57% as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Recce Pharmaceuticals Business Description

Other Exchanges RCE:Australia
Address 3 Brodie Hall Drive, Suite 10, Technology Park, Bentley, WA, AUS, 6102
Recce Pharmaceuticals Ltd is an Australia-based, globally-focused biotechnology company that is pioneering the development and commercialisation of a drug discovery and development business commercialising new Classes of synthetic anti-infectives with broad-spectrum activity designed to address the urgent health threat of antibiotic-resistant superbugs and emerging viral pathogens. Its patented candidate, RECCE 327, has been developed for the treatment of life-threatening bacterial infections. It has one segment, which is the research and development of pharmaceutical drugs. Geographic segments are Australia, the UK, and the USA, of which the majority of the revenue comes from Australia. It offers antibiotic drugs to treat bacterial infections for Sepsis, Escherichia coli, and Others.
23GF Score

Get the complete analysis for FRA:R9Q

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price